| Literature DB >> 30563015 |
Oh-Seok Kwon1, Donghwa Kim2, Heegyu Kim3, Yeon-Ju Lee4, Hyi-Seung Lee5, Chung J Sim6, Dong-Chan Oh7, Sang Kook Lee8, Ki-Bong Oh9, Jongheon Shin10.
Abstract
Two new sceptrin derivatives (1,2) and eight structurally-related known bromopyrrole-bearing alkaloids were isolated from the tropical sponge Agelas kosrae. By a combination of spectroscopic methods, the new compounds, designated dioxysceptrin (1) and ageleste C (2), were determined to be structural analogs of each other that differ at the imidazole moiety. Dioxysceptrin was also found to exist as a mixture of α-amido epimers. The sceptrin alkaloids exhibited weak cytotoxicity against cancer cells. Compounds 1 and 2 also moderately exhibited anti-angiogenic and isocitrate lyase-inhibitory activities, respectively.Entities:
Keywords: anti-angiogenesis; bioactive marine natural products; isocitrate lyase; marine sponge; pyrrole-imidazole alkaloids; sceptrin
Mesh:
Substances:
Year: 2018 PMID: 30563015 PMCID: PMC6316234 DOI: 10.3390/md16120513
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1The structures of compounds 1–10.
NMR spectral data for compounds 1 and 2 in DMSO-d6 (600 MHz).
| Position | 1a | 1b | 2 | |||
|---|---|---|---|---|---|---|
| δH, mult ( | δC (Type) | δH, mult ( | δC (Type) | δH, mult ( | δC (Type) | |
| 1/1′ | 11.73, br s | 11.79, br s | 11.80, br s | |||
| 2/2′ | 6.95, m | 121.3 (CH) | 6.98, m | 121.3 (CH) | 6.97, dd (2.7, 1.5) | 121.2 (CH) |
| 3/3′ | 95.1 (C) | 95.0 (C) | 94.9 (C) | |||
| 4/4′ | 6.84, m | 111.8 (CH) | 6.85, m | 111.6 (CH) | 6.84, dd (2.7, 1.5) | 111.5 (CH) |
| 5/5′ | 126.6 (C) | 126.7 (C) | 126.7 (C) | |||
| 6/6′ | 160.2 (C) | 160.0 (C) | 160.0 (C) | |||
| 7/7′ | 8.04, t (5.7) | 8.24, t (5.7) | 8.19, t (5.8) | |||
| 8/8′ | 3.26, m; 3.13, m | 41.9 (CH2) | 3.33, m; 3.27, m | 41.6 (CH2) | 3.36, m; 3.25, m | 40.8 (CH2) |
| 9/9′ | 2.08, m | 37.1 (CH) | 2.07, m | 38.2 (CH) | 2.25, m | 38.9 (CH) |
| 10/10′ | 2.47, m | 38.2 (CH) | 2.46, m | 36.7 (CH) | 2.83, m | 40.5 (CH) |
| 11/11′ | 4.45, s | 60.3 (CH) | 4.28, s | 60.0 (CH) | 174.0 (C) | |
| 12/12′ | 10.01, s | 10.07, s | ||||
| 13/13′ | 158.7 (C) | 158.7 (C) | ||||
| 14/14′ | ||||||
| 15/15′ | 174.3 (C) | 174.1 (C) | ||||
| 16/16′ | 9.16, br s | 9.16, br s | ||||
Figure 2Key COSY (bold), HMBC (arrows), and ROESY (dashed arrows) correlations of compounds 1 and 2.
Figure 3Experimental and calculated ECD spectra of 1.
Results of bioactivity test.
| IC50 (μM) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Proliferation | Anti-Angiogenesis | |||||||||
| Compound | K562 | A549 | HCT 116 | MDA-MB-231 | SNU 638 | SK-Hep-1 | Tube Formation | Cell Viability | ICL | |
|
| 12.87 | 31.32 | 9.93 | 32.83 | 7.92 | 35.19 | 7.99 | >40 | >100 | |
|
| 19.13 | 49.32 | 44.06 | >50 | 36.77 | >50 | >40 | >40 | 22.09 | |
|
| 37.61 | >50 | >50 | >50 | >50 | >50 | >40 | >40 | >100 | |
|
| 26.42 | 30.5 | 38.19 | >50 | 37.06 | >50 | >40 | >40 | 85.31 | |
| Doxorubicin | 1.08 | |||||||||
| Etoposide | 0.83 | 0.73 | 3.12 | 0.63 | 0.74 | |||||
| Sunitinib | 2.41 | 9.92 | ||||||||
| 3-NP | 11.09 | |||||||||
Figure 4Anti-angiogenic activity of compound 1. (a) Inhibitory effects of compound 1 in vascular tube formation induced by VEGF were visualized using optical microscopy. (b) The lengths of tubes were quantified and compared to the VEGF-treated control. (c) Cell viability after treatment of compound 1 in the presence of VEGF for 24 h was measured by MTT and compared to the control. Data are presented as the mean fold changes ± SD of three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.005 by t-test.